NCT05136131 QOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT)
| NCT ID | NCT05136131 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ottawa Heart Institute Research Corporation |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-10 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-02-10 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is a type of irregular heart rhythm due to electrical signal disturbances of the heart. It is a very common arrhythmia and the risk of developing AF increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The main complications of AF are heart failure and stroke. However, studies have shown that restoration of normal rhythm does not reduce these complications. Rather, these complications are mitigated by controlling the heart rate and using blood thinners to prevent stroke. Symptoms secondary to AF can occur due to the irregular heart rate and poor contraction in the atria, the top chambers of the heart. These symptoms include shortness of breath, fatigue, reduced exercise tolerance, and palpitations. Restoring sinus rhythm can sometimes alleviate these symptoms. Given that studies to date have not shown a difference in hard clinical endpoints between rate and rhythm control strategies, the decision to proceed with rhythm control depends on the patient symptom burden. Rhythm control strategies in patients with persistent AF include cardioversion back to sinus rhythm with long-term recurrence prevention via anti-arrhythmic drugs (AADs) or catheter ablation. However, many studies of these procedures omit a sham placebo control arm. No atrial fibrillation procedural intervention has been compared to a sham procedure. The cardioversion procedure can easily be compared to a "sham" alternative, as it is non-invasive with an expected response within days-to-weeks. Thus, a cardioversion versus "sham" cardioversion trial will allow us to truly assess the impact of a rhythm-control strategy on QOL. It is hypothesized that cardioversion of atrial fibrillation leads to significant improvement in quality of life (QOL) compared to sham cardioversion. Understanding the true QOL impact of sinus rhythm restoration in patients with persistent AF is of significant importance in guiding strategies for the management of AF. Hence, by evaluating what the true effect of cardioversion on QOL in this blinded study, we can better understand the role of medical management and AF ablation in our patients and assess resource allocation to these procedures.
Eligibility Criteria
Inclusion Criteria: * Patients age ≥ 18 years * Persistent atrial fibrillation * Unknown symptom burden related to AF Exclusion Criteria: * Known left-atrial appendage thrombus * Prior catheter or surgical ablation for AF * Intolerance or contraindication to Amiodarone * Contraindication to appropriate anticoagulation * Patient is included in another randomized clinical trial * Patient is unable or unwilling to provide informed consent * Patient with a history of noncompliance with medical therapy * Patient does not meet all of the above listed inclusion criteria * Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrolment) * Breastfeeding * Patients for whom the investigator believes that the trial is not in the interest of the patient
Contact & Investigator
David Birnie, MD
PRINCIPAL INVESTIGATOR
Ottawa Heart Institute Research Corporation
Frequently Asked Questions
Who can join the NCT05136131 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05136131 currently recruiting?
Yes, NCT05136131 is actively recruiting participants. Contact the research team at tknight@ottawaheart.ca for enrollment information.
Where is the NCT05136131 trial being conducted?
This trial is being conducted at Newmarket, Canada, Ottawa, Canada.
Who is sponsoring the NCT05136131 clinical trial?
NCT05136131 is sponsored by Ottawa Heart Institute Research Corporation. The principal investigator is David Birnie, MD at Ottawa Heart Institute Research Corporation. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.